Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Solomon

Showing results (301-310 of 1,211) with videos related to

Pageof 122
Sort By:
JAMA Cardiology|November 15, 2016
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF TrialAkshay S Desai, Orly Vardeny, Brian Claggett, et al.
JACC. Heart Failure|May 15, 2013
Heart failure with preserved ejection fraction in African Americans: The ARIC (Atherosclerosis Risk In Communities) studyDeepak K Gupta, Amil M Shah, Davide Castagno, et al.
Circulation|December 7, 2005
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patientsScott D Solomon, Nagesh Anavekar, Hicham Skali, et al.
The American Journal of Medicine|April 25, 2015
American Heart Association's Life's Simple 7: Avoiding Heart Failure and Preserving Cardiac Structure and FunctionAaron R Folsom, Amil M Shah, Pamela L Lutsey, et al.
European Journal of Heart Failure|January 30, 2009
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)Nathaniel M Hawkins, Zhen Huang, Karen S Pieper, et al.
Journal of the American Heart Association|November 19, 2021
Depressive Symptoms, Cardiac Structure and Function, and Risk of Incident Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction in Late LifeKatja Vu, Brian L Claggett, Jenine E John, et al.
JAMA Cardiology|November 5, 2022
Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the USKhawaja M Talha, Javed Butler, Stephen J Greene, et al.
European Journal of Heart Failure|January 28, 2014
The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patientsGeorge V Moukarbel, Zi-Fan Yu, Kenneth Dickstein, et al.
Journal of the American Heart Association|May 17, 2021
Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection FractionSenthil Selvaraj, Brian L Claggett, Milton Packer, et al.
JACC. Heart Failure|February 4, 2022
Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HFPeder L Myhre, Margaret F Prescott, Sean P Murphy, et al.
Pageof 122

Showing results (301-310 of 1,211) with videos related to

Sort By:
Pageof 122
JAMA Cardiology|November 15, 2016
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF TrialAkshay S Desai, Orly Vardeny, Brian Claggett, et al.
JACC. Heart Failure|May 15, 2013
Heart failure with preserved ejection fraction in African Americans: The ARIC (Atherosclerosis Risk In Communities) studyDeepak K Gupta, Amil M Shah, Davide Castagno, et al.
Circulation|December 7, 2005
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patientsScott D Solomon, Nagesh Anavekar, Hicham Skali, et al.
The American Journal of Medicine|April 25, 2015
American Heart Association's Life's Simple 7: Avoiding Heart Failure and Preserving Cardiac Structure and FunctionAaron R Folsom, Amil M Shah, Pamela L Lutsey, et al.
European Journal of Heart Failure|January 30, 2009
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)Nathaniel M Hawkins, Zhen Huang, Karen S Pieper, et al.
Journal of the American Heart Association|November 19, 2021
Depressive Symptoms, Cardiac Structure and Function, and Risk of Incident Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction in Late LifeKatja Vu, Brian L Claggett, Jenine E John, et al.
JAMA Cardiology|November 5, 2022
Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the USKhawaja M Talha, Javed Butler, Stephen J Greene, et al.
European Journal of Heart Failure|January 28, 2014
The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patientsGeorge V Moukarbel, Zi-Fan Yu, Kenneth Dickstein, et al.
Journal of the American Heart Association|May 17, 2021
Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection FractionSenthil Selvaraj, Brian L Claggett, Milton Packer, et al.
JACC. Heart Failure|February 4, 2022
Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HFPeder L Myhre, Margaret F Prescott, Sean P Murphy, et al.
Pageof 122